AI-Powered Prostate Cancer Research

mCRPC represents the most challenging phase of prostate cancer. AI agents research PSMA-targeted therapies, PARP inhibitors, and novel androgen receptor approaches.

Get a $99 personalized brief on Prostate Cancer

14 specialist agents compile a 30–50 page brief from PubMed-indexed research, delivered in 48 hours. Refund + free re-brief if not useful.

Standard of Care

Androgen deprivation + novel hormonal agents (enzalutamide, abiraterone), docetaxel/cabazitaxel, PSMA-targeted radioligand (Lu-177 PSMA-617), PARP inhibitors (BRCA+).

Prevalence

~300,000 new prostate cancer diagnoses per year in the US. ~35,000 deaths.

Five-Year Survival

Stage IV: ~32%. With PSMA-targeted therapy: improving.

Key Mutations

BRCA1/2
ATM
CDK12
PTEN loss
AR amplification
MSI-H/dMMR

Key Pathways

androgen-receptor-signaling
dna-damage-repair
pi3k-akt-mtor

Clinical Trial Focus

PSMA-targeted bispecifics, PSMA-CAR-T, bipolar androgen therapy, CDK12 loss-targeted immunotherapy.